Skip to content
Inciteful Med

What is GNE Myopathy? Validation & Orientation

Last updated:

GNE myopathy is a rare, adult-onset genetic muscle disease that causes progressive weakness, often starting with foot drop. While it progresses slowly and uniquely spares the quadriceps, new treatments targeting the underlying GNE gene mutation are bringing hope to newly diagnosed patients.

Key Takeaways

  • • GNE myopathy is a rare, slowly progressive genetic muscle disease caused by a mutation in the GNE gene.
  • • The condition usually begins in early adulthood with foot drop, but uniquely spares the large quadriceps muscles in the thighs.
  • • Due to its rarity, patients often experience a diagnostic delay of over five years before receiving a correct genetic diagnosis.
  • • New therapies are advancing, including the recent approval of Aceneuramic acid in Japan and ongoing global clinical trials for gene therapy.

Finding out you have GNE Myopathy (also known as HIBM or Nonaka Myopathy) can be a moment of both intense relief and new anxiety. If you have spent years visiting different specialists, being told it might be “just” a back issue or a different muscle disease, your experience is common. This is a very rare condition, affecting only about 1 to 9 people per million worldwide [1]. Because it is so rare, you may find that you quickly become more of an expert on your condition than many of the doctors you encounter.

Validating Your Journey

The “diagnostic odyssey”—the long period between your first symptoms and an accurate diagnosis—is a hallmark of GNE myopathy. On average, patients wait more than 5 years to receive a correct diagnosis [2]. Early symptoms, like foot drop (difficulty lifting the front part of the foot), are often mistaken for common nerve or spine issues [3][4]. It is important to know that this delay was not your fault; the disease’s rarity and its overlap with other muscle conditions make it difficult for even experienced neurologists to identify without specific genetic testing [5][6].

What is GNE Myopathy?

GNE myopathy is an adult-onset genetic muscle disease. Most people begin to notice symptoms in their late teens, 20s, or 30s [7][3]. It is autosomal recessive, meaning it only occurs when a person inherits two changed (mutated) copies of the GNE gene, one from each parent [8][9].

The biological cause is a process called hyposialylation [8]:

  • The Gene’s Job: The GNE gene provides instructions for making an enzyme that is the “bottleneck” or “master switch” for creating sialic acid [1].
  • The Problem: In GNE myopathy, this enzyme doesn’t work correctly, leading to a severe shortage of sialic acid in your muscles—sometimes as much as a 72-85% reduction [10].
  • The Result: Sialic acid is like a protective coating on the surface of your muscle cells. Without enough of it, muscle fibers gradually weaken and can develop rimmed vacuoles (small “bubbles” or holes seen under a microscope) [11][1].

Stabilizing Facts for the Road Ahead

While a diagnosis of a progressive muscle disease is life-changing, there are several reasons for hope and stability:

  1. Quadriceps Sparing: A unique and stabilizing feature of this disease is that the quadriceps (the large muscles in the front of your thighs) often remain strong even as other muscles weaken [1][12]. This often helps patients maintain the ability to walk for longer than in many other muscle diseases.
  2. Therapies are Advancing: In March 2024, Japan’s regulatory agency approved the first-ever treatment specifically for GNE myopathy: an extended-release form of Aceneuramic acid (brand name Acenobel or Acediur) [13][14]. While access outside of Japan is currently complex due to mixed trial results globally, this proves that targeting the disease biology is possible.
  3. Active Research: Beyond the drug approved in Japan, researchers are actively testing other compounds like ManNAc (a building block for sialic acid) and exploring gene therapy to address the root cause of the disease [15][16].
  4. Manageable Pace: While the disease is progressive, it typically moves slowly over decades, allowing time to adapt and plan [17].

You are now part of a small but dedicated global community. Connecting with patient registries and advocacy groups can help you stay informed as more treatments move through clinical trials [12][2].

Frequently Asked Questions

What causes GNE myopathy?
GNE myopathy is an autosomal recessive genetic condition caused by mutations in the GNE gene. This mutation impairs an enzyme needed to create sialic acid, which protects muscle cells, ultimately leading to gradual muscle weakness.
What are the first symptoms of GNE myopathy?
The earliest symptom is usually foot drop, which is difficulty lifting the front part of the foot, causing people to trip or drag their toes. Symptoms typically begin in a person's late teens, 20s, or 30s.
Are there any treatments for GNE myopathy?
While there is no worldwide cure yet, research is advancing. In 2024, Japan approved Aceneuramic acid as the first specific treatment for the condition. Additionally, researchers are actively testing other compounds and exploring gene therapy in clinical trials.
Will I lose the ability to walk with GNE myopathy?
While the disease causes progressive muscle weakness over decades, a unique feature is that it usually spares the quadriceps muscles in the thighs. This quadriceps sparing often helps patients maintain the ability to walk longer than those with other muscle diseases.
Why does GNE myopathy take so long to diagnose?
Because the condition is extremely rare and shares early symptoms with common nerve or spine issues, it often takes years to diagnose. A definitive diagnosis requires specific genetic testing to identify the mutated GNE gene.

Questions for Your Doctor

  • • What is my specific GNE mutation, and how might it influence my disease progression?
  • • Are you familiar with the recent approval of Aceneuramic acid (Acenobel) in Japan, and is there any expanded access program available in our country?
  • • Can you refer me to a physical therapist who specializes in neuromuscular diseases to help with my foot drop and mobility?
  • • Should we monitor my breathing or platelet counts, given that GNE myopathy can sometimes affect these?
  • • Are there any ongoing clinical trials for ManNAc or gene therapy that I might be eligible for?

Questions for You

  • • How long did it take from my first symptoms to getting this diagnosis, and what were the most challenging parts of that journey?
  • • Which of my daily activities are most affected by muscle weakness right now, and what tools (like orthotics) might help me stay active?
  • • How do I feel about sharing this diagnosis with my family, especially considering its genetic nature?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    GNE Myopathy: Etiology, Diagnosis, and Therapeutic Challenges.

    Carrillo N, Malicdan MC, Huizing M

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018; (15(4)):900-914 doi:10.1007/s13311-018-0671-y.

    PMID: 30338442
  2. 2

    Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: First report from the GNE myopathy Disease Monitoring Program, registry portion.

    Pogoryelova O, Cammish P, Mansbach H, et al.

    Neuromuscular disorders : NMD 2018; (28(2)):158-168 doi:10.1016/j.nmd.2017.11.001.

    PMID: 29305133
  3. 3

    Long term clinical follow-up and natural history in a cohort of Italian patients with GNE myopathy: the experience of a single centre.

    Pugliese A, Sframeli M, D'Ambrosio P, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(9)):4645-4652 doi:10.1007/s10072-025-08265-w.

    PMID: 40447857
  4. 4

    Hereditary inclusion body myopathy: A myopathy with unique topography of weakness, yet frequently misdiagnosed: Case series and review of literature.

    Das B, Goyal MK, Bhatkar SR, et al.

    Annals of Indian Academy of Neurology 2016; (19(1)):119-22 doi:10.4103/0972-2327.167709.

    PMID: 27011643
  5. 5

    A novel application of tau PET in the diagnosis of sporadic inclusion body myositis: A case report.

    Zhang Y, Li K, Pu C, et al.

    Medicine 2020; (99(31)):e21524 doi:10.1097/MD.0000000000021524.

    PMID: 32756195
  6. 6

    A female carrier of spinal and bulbar muscular atrophy diagnosed with DNAJB6-related distal myopathy.

    Xu L, Geng H, Lv X, et al.

    Journal of human genetics 2022; (67(7)):441-444 doi:10.1038/s10038-022-01022-3.

    PMID: 35165376
  7. 7

    GNE myopathy: History, etiology, and treatment trials.

    Mullen J, Alrasheed K, Mozaffar T

    Frontiers in neurology 2022; (13()):1002310 doi:10.3389/fneur.2022.1002310.

    PMID: 36330422
  8. 8

    [GNE myopathy].

    Urtizberea JA, Béhin A

    Medecine sciences : M/S 2015; (31 Spec No 3()):20-7 doi:10.1051/medsci/201531s306.

    PMID: 26546927
  9. 9

    [Efficacy of Aceneuramic Acid for Distal Myopathy with Rimmed Vacuoles].

    Aoki M, Izumi R, Suzuki N

    Brain and nerve = Shinkei kenkyu no shinpo 2023; (75(10)):1149-1154 doi:10.11477/mf.1416202492.

    PMID: 37849366
  10. 10

    Substantial deficiency of free sialic acid in muscles of patients with GNE myopathy and in a mouse model.

    Chan YM, Lee P, Jungles S, et al.

    PloS one 2017; (12(3)):e0173261 doi:10.1371/journal.pone.0173261.

    PMID: 28267778
  11. 11

    Muscle biopsy and UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene mutation analysis in two Chinese patients with distal myopathy with rimmed vacuoles.

    Liu N, Wang ZK, Wang HX, et al.

    Neuroreport 2015; (26(10)):598-601 doi:10.1097/WNR.0000000000000396.

    PMID: 26053703
  12. 12

    [Sialic Acid Replacement Therapy for Distal Myopathy with Rimmed Vacuoles].

    Mori-Yoshimura M, Nishino I

    Brain and nerve = Shinkei kenkyu no shinpo 2015; (67(9)):1115-23 doi:10.11477/mf.1416200269.

    PMID: 26329152
  13. 13

    Ultra-Orphan drug development for GNE Myopathy: A synthetic literature review and meta-analysis.

    Suzuki N, Mori-Yoshimura M, Nishino I, Aoki M

    Journal of neuromuscular diseases 2025; (12(2)):183-194 doi:10.1177/22143602241296226.

    PMID: 39973407
  14. 14

    Decoding GNE Myopathy: From Molecular Basis to Therapeutic Advances.

    Yoshioka W, Noguchi S, Nishino I

    Annals of Indian Academy of Neurology 2025; (28(5)):631-639 doi:10.4103/aian.aian_837_25.

    PMID: 41082181
  15. 15

    Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study.

    Carrillo N, Malicdan MC, Leoyklang P, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(11)):2067-2075 doi:10.1038/s41436-021-01259-x.

    PMID: 34257421
  16. 16

    Recent advances in establishing a cure for GNE myopathy.

    Yoshioka W, Nishino I, Noguchi S

    Current opinion in neurology 2022; (35(5)):629-636 doi:10.1097/WCO.0000000000001090.

    PMID: 35959526
  17. 17

    Large phenotypic diversity by genotype in patients with GNE myopathy: 10 years after the establishment of a national registry in Japan.

    Yoshioka W, Nakamura H, Oba M, et al.

    Journal of neurology 2024; (271(7)):4453-4461 doi:10.1007/s00415-024-12396-z.

    PMID: 38691167

This page provides educational information about GNE myopathy for newly diagnosed patients and their families. Always consult your neurologist or genetic counselor for medical advice regarding your specific condition and treatment options.

Stay up to date

Get notified when new research about GNE myopathy is published.

No spam. Unsubscribe anytime.